Relay Therapeutics to Participate in Upcoming Investor Conferences

RLAY 11.07.2024

Full Press ReleaseSEC FilingsOur RLAY Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - January 14, 2025 10:30 AM EST - January 14, 2025 11:10 AM EST : Relay Therapeutics at the 43rd Annual J.P. Morgan Healthcare Conference
  • 01.07.2025 - Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.22.2025 - 144 Report of proposed sale of securities
  • 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - 8-K Current report
PDF Version

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) --Relay Therapeutics, Inc.(Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats:

  • Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ET
  • Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:55 a.m. ET
  • Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 6:30 a.m. ET (11:30 a.m. GMT)
  • The Citizens JMP Hematology and Oncology Summit, taking place virtually on Monday, December 2, 2024 at 1:30 p.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link:https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.

About Relay TherapeuticsRelay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visitwww.relaytx.comorfollow us on Twitter.

Contact:Megan Goulart617-545-5526mgoulart@relaytx.com

Media:Dan Budwick1AB973-271-6085dan@1abmedia.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com